Jiang‐Jiang Qin

8.3k total citations · 5 hit papers
175 papers, 5.8k citations indexed

About

Jiang‐Jiang Qin is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Jiang‐Jiang Qin has authored 175 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 128 papers in Molecular Biology, 62 papers in Oncology and 51 papers in Cancer Research. Recurrent topics in Jiang‐Jiang Qin's work include Natural product bioactivities and synthesis (41 papers), Sesquiterpenes and Asteraceae Studies (32 papers) and Cancer-related Molecular Pathways (28 papers). Jiang‐Jiang Qin is often cited by papers focused on Natural product bioactivities and synthesis (41 papers), Sesquiterpenes and Asteraceae Studies (32 papers) and Cancer-related Molecular Pathways (28 papers). Jiang‐Jiang Qin collaborates with scholars based in China, United States and Macao. Jiang‐Jiang Qin's co-authors include Weidong Zhang, Xiangdong Cheng, Ruiwen Zhang, Jinyun Dong, Weidong Zhang, Subhasree Nag, Zhiyuan Xu, Hui‐Zi Jin, Yuan Li and Sukesh Voruganti and has published in prestigious journals such as Nature Communications, Gastroenterology and PLoS ONE.

In The Last Decade

Jiang‐Jiang Qin

168 papers receiving 5.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review

2019 306 citations Jiang‐Jiang Qin, Weidong Zhang et al. profile →
Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance

2020 237 citations Yuan Li, Zhiyuan Xu et al. Molecular Cancer profile →
PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

2021 209 citations Simin Qi, Jinyun Dong et al. profile →
Targeting KRAS mutant cancers: from druggable therapy to drug resistance

2022 136 citations Xiaoqing Guan, Xinuo Zhang et al. Molecular Cancer profile →
Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): An updated review

2023 85 citations Jinyun Dong, Yuan Li et al. profile →

Peers

Countries citing papers authored by Jiang‐Jiang Qin

Since Specialization

Citations

This map shows the geographic impact of Jiang‐Jiang Qin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiang‐Jiang Qin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiang‐Jiang Qin more than expected).

Fields of papers citing papers by Jiang‐Jiang Qin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiang‐Jiang Qin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiang‐Jiang Qin. The network helps show where Jiang‐Jiang Qin may publish in the future.

Co-authorship network of co-authors of Jiang‐Jiang Qin

This figure shows the co-authorship network connecting the top 25 collaborators of Jiang‐Jiang Qin. A scholar is included among the top collaborators of Jiang‐Jiang Qin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiang‐Jiang Qin. Jiang‐Jiang Qin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Harnessing the Power of Natural Products for Targeted Protein Degradation 2025 ·Medicinal Research Reviews ·(unknown), Wu Zheng, (unknown), Kaili Zhao, (unknown), Jiang‐Jiang Qin, Hongwei Guo	0
2	An updated review on the role of small molecules in mediating protein degradation 2025 ·European Journal of Medicinal Chemistry ·(unknown), Yulong Li, Jinyun Dong, Jiang‐Jiang Qin	4
3	Decoding the microbiota metabolome in hepatobiliary and pancreatic cancers: Pathways to precision diagnostics and targeted therapeutics 2024 ·Pharmacological Research ·(unknown), (unknown), Jiang‐Jiang Qin, Yuhua Zhang, Jiaying Yang, Zhuo Chen, Changyu Li, Qian Xiang, (unknown)	4
4	Application of biomimetic nanovaccines in cancer immunotherapy: A useful strategy to help combat immunotherapy resistance 2024 ·Drug Resistance Updates ·Zhijie Xu, (unknown), Tongfei Li, Qiaoli Yi, Abhimanyu Thakur, (unknown), Xuelei Ma, Jiang‐Jiang Qin, Yuanliang Yan	23
5	Mechanisms of traditional Chinese medicine in the treatment and prevention of gastric cancer 2024 ·Phytomedicine ·Yanyang Liu, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jie Xuan, Jiang‐Jiang Qin, Qinglin Li	11
6	ML162 derivatives incorporating a naphthoquinone unit as ferroptosis/apoptosis inducers: Design, synthesis, anti-cancer activity, and drug-resistance reversal evaluation 2024 ·European Journal of Medicinal Chemistry ·(unknown), Yulong Li, Maohua Cai, Wenyan Yang, (unknown), Jinyun Dong, Jiang‐Jiang Qin	14
7	A Critical Assessment for Hualer, A Traditional Chinese Medicine, for Cancer Therapy: Medicinal Characteristics, Molecular Mechanisms of Action, In-Vitro and In-Vivo Anticancer Activities, and Future Research Directions 2024 ·Xinuo Zhang, Shengqiang Tong, Jiang‐Jiang Qin, Xiaoqing Guan	0
8	Heat Shock Protein 90 Interactome-Mediated Proteolysis Targeting Chimera (HIM-PROTAC) Degrading Glutathione Peroxidase 4 to Trigger Ferroptosis 2024 ·Journal of Medicinal Chemistry ·Jinyun Dong, (unknown), Maohua Cai, (unknown), Haobin Li, Hui Liang, Yulong Li, Guangyu Ding, Juan Li, (unknown), Jiang‐Jiang Qin	17
9	Blocking Ubiquitin‐Specific Protease 7 Induces Ferroptosis in Gastric Cancer via Targeting Stearoyl‐CoA Desaturase 2024 ·Advanced Science ·Xiaoqing Guan, Yichao Wang, Wen-Kai Yu, (unknown), (unknown), Enyu Dai, Xiaowu Dong, Bing Zhao, Can Hu, Yuan Li, Xin Luan, Kai Miao, Bonan Chen, Xiangdong Cheng, Weidong Zhang, Jiang‐Jiang Qin	39
10	Small molecule inhibitors targeting heat shock protein 90: An updated review 2024 ·European Journal of Medicinal Chemistry ·Yulong Li, Jinyun Dong, Jiang‐Jiang Qin	10
11	Expanding the ubiquitin code in pancreatic cancer 2023 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·Wenyan Yang, Shiqun Wang, Shengqiang Tong, Weidong Zhang, Jiang‐Jiang Qin	6
12	Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer 2022 ·JCI Insight ·Jinmei Jin, Yaping Wu, (unknown), Ye Wu, Yudong Zhou, Sanhong Liu, Qingyan Sun, Guizhu Yang, Jiayi Lin, Dale G. Nagle, Jiang‐Jiang Qin, Zhiyuan Zhang, Hongzhuan Chen, Weidong Zhang, Shuyang Sun, Xin Luan	41
13	Targeting E2 ubiquitin-conjugating enzyme UbcH5c by small molecule inhibitor suppresses pancreatic cancer growth and metastasis 2022 ·Molecular Cancer ·Simin Qi, Xiaoqing Guan, Jia Zhang, Dehua Yu, Xuefei Yu, Qinglin Li, Wenjuan Yin, Xiangdong Cheng, Weidong Zhang, Jiang‐Jiang Qin	27
14	Biodegradable iron oxide nanoparticles for intraoperative parathyroid gland imaging in thyroidectomy 2022 ·PNAS Nexus ·Weihui Zheng, (unknown), Jiaoyue Jin, Wei Sun, Jianqiang Zhao, (unknown), (unknown), (unknown), Fan Chen, (unknown), Kejing Wang, Peng Guo, Jiang‐Jiang Qin, Xiangdong Cheng	5
15	Synergistic effects of autophagy/mitophagy inhibitors and magnolol promote apoptosis and antitumor efficacy 2021 ·Acta Pharmaceutica Sinica B ·Yancheng Tang, Liming Wang, Tao Yi, Jun Xu, Jigang Wang, Jiang‐Jiang Qin, Qilei Chen, (unknown), Yihang Pan, Hong Peng, Yingying Lü, Han‐Ming Shen, Hubiao Chen	44
16	Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation 2021 ·Journal of Medicinal Chemistry ·Jinyun Dong, Xiangdong Cheng, Weidong Zhang, Jiang‐Jiang Qin	157
17	The role of miRNAs in MDMX‐p53 interplay 2021 ·Journal of Evidence-Based Medicine ·Dehua Yu, Zhiyuan Xu, Xiangdong Cheng, Jiang‐Jiang Qin	4
18	Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance breakdown → 2020 ·Molecular Cancer ·Yuan Li, Zhiyuan Xu, Shanming Ruan, Shaowei Mo, Jiang‐Jiang Qin, Xiangdong Cheng	237
19	Dual roles and therapeutic potential of Keap1-Nrf2 pathway in pancreatic cancer: a systematic review 2019 ·Cell Communication and Signaling ·Jiang‐Jiang Qin, Xiangdong Cheng, Jia Zhang, Weidong Zhang	75
20	Japonicone A Suppresses Growth of Burkitt Lymphoma Cells through Its Effect on NF-κB 2013 ·Clinical Cancer Research ·Xiaoguang Li, Xinying Yang, Yanling Liu, (unknown), Wenbo Yao, Peizhan Chen, Jiang‐Jiang Qin, Hui‐Zi Jin, Jingquan Li, Ruiai Chu, Lei Shan, Ruiwen Zhang, Weidong Zhang, Hui Wang	40

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact